Candriam SCA’s Enanta Pharmaceuticals ENTA Stock Holding History

Candriam SCA’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-40,507	Closed	-$1.51M	–	771
2023 Q1	$1.51M	Sell	40,507 -60,000	-60%	-$2.87M	0.01%	631
2022 Q4	$4.68M	Hold	100,507	–	–	0.03%	392
2022 Q3	$5.21M	Sell	100,507 -14,000	-12%	-$818K	0.04%	367
2022 Q2	$5.41M	Hold	114,507	–	–	0.04%	316
2022 Q1	$8.15M	Sell	114,507 -46,851	-29%	-$3.05M	0.06%	280
2021 Q4	$12.1M	Buy	+161,358	New	+$12.7M	0.08%	236
2021 Q2	–	Sell	-178,941	Closed	-$7.24M	–	910
2021 Q1	$7.24M	Hold	178,941	–	–	0.06%	311
2020 Q4	$7.53M	Buy	178,941 +114,907	+179%	+$5.06M	0.06%	319
2020 Q3	$2.93M	Buy	+64,034	New	+$3.1M	0.03%	442
2020 Q2	–	Sell	-110,139	Closed	-$6.65M	–	823
2020 Q1	$6.65M	Hold	110,139	–	–	0.07%	285
2019 Q4	$6.8M	Sell	110,139 -4,861	-4%	-$301K	0.07%	291
2019 Q3	$6.91M	Buy	115,000 +50,000	+77%	+$3.71M	0.09%	256
2019 Q2	$5.46M	Hold	65,000	–	–	0.07%	312
2019 Q1	$6.21M	Buy	65,000 +3,000	+5%	+$269K	0.08%	278
2018 Q4	$4.39M	Buy	+62,000	New	+$4.75M	0.07%	307
2018 Q3	–	Sell	-12,500	Closed	-$1.45M	–	820
2018 Q2	$1.45M	Sell	12,500 -12,000	-49%	-$1.2M	0.02%	542
2018 Q1	$1.98M	Sell	24,500 -43,500	-64%	-$3.35M	0.03%	484
2017 Q4	$3.99M	Sell	68,000 -157,000	-70%	-$7.86M	0.07%	313
2017 Q3	$10.5M	Sell	225,000 -85,000	-27%	-$3.42M	0.18%	152
2017 Q2	$11.2M	Sell	310,000 -46,000	-13%	-$1.47M	0.21%	129
2017 Q1	$11M	Buy	356,000 +120,000	+51%	+$3.74M	0.21%	135
2016 Q4	$7.91M	Sell	236,000 -6,000	-2%	-$172K	0.18%	143
2016 Q3	$6.44M	Buy	+242,000	New	+$5.62M	0.15%	158
2016 Q2	–	Sell	-162,000	Closed	-$4.73M	–	663
2016 Q1	$4.73M	Buy	162,000 +56,000	+53%	+$1.56M	0.12%	206
2015 Q4	$3.5M	Buy	+106,000	New	+$3.45M	0.09%	231
2015 Q3	–	Sell	-45,000	Closed	-$2.02M	–	629
2015 Q2	$2.02M	Buy	+45,000	New	+$1.75M	0.04%	363
2015 Q1	–	Sell	-35,000	Closed	-$1.78M	–	644
2014 Q4	$1.78M	Buy	+35,000	New	+$1.57M	0.04%	370

Other funds holding ENTA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Candriam SCA's ENTA Position: Q2 2023 in Review

Candriam SCA sold out of Enanta Pharmaceuticals (ENTA) in Q2 2023, closing a stake of 40,507 shares — an estimated $1.51M sold.

Candriam SCA first reported a position in ENTA in Q4 2014 and held it in 27 quarters. The position peaked at $12.1M in Q4 2021. 133 funds tracked by Wall St. Rank hold ENTA as of Q2 2023.

Candriam SCA reported no remaining Enanta Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Candriam SCA sold 40,507 Enanta Pharmaceuticals shares in Q2 2023, an estimated $1.51M.
Candriam SCA first reported a position in Enanta Pharmaceuticals in Q4 2014 and held it in 27 quarters.
Candriam SCA's Enanta Pharmaceuticals position peaked at $12.1M in Q4 2021.
133 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2023.

Based on Candriam SCA's 13F filing for Q2 2023, filed 8 Aug 2023.